Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We assessed the prognostic value of hypoxia (carbonic anhydrase 9; CA9), vessel density (CD31), with macrophages (CD68) and B cells (CD20) that can interact and lead to immune suppression and disease progression using scanning and histological mapping of whole-mount FFPE pancreatectomy tissue sections from 141 primarily resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with surgery and adjuvant chemotherapy. Their expression was correlated with clinicopathological characteristics, and overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), also in the context of stroma density (haematoxylin-eosin) and activity (alpha-smooth muscle actin). The median OS was 21 months after a mean follow-up of 20 months (range, 2-69 months). The median tumor surface area positive for CA9 and CD31 was 7.8% and 8.1%, respectively. Although total expression of these markers lacked prognostic value in the entire cohort, nevertheless, high tumor compartment CD68 expression correlated with worse PFS (p = 0.033) and DMFS (p = 0.047). Also, high CD31 expression predicted for worse OS (p = 0.004), PFS (p = 0.008), LPFS (p = 0.014) and DMFS (p = 0.004) in patients with moderate density stroma. High stromal and peripheral compartment CD68 expression predicted for significantly worse outcome in patients with loose and moderate stroma density, respectively. Altogether, in contrast to the current notion, hypoxia levels in PDAC appear to be comparable to other malignancies. CD31 and CD68 constitute prognostic markers in patient subgroups that vary according to tumor compartment and stromal density. Our study provides important insight on the pathophysiology of PDAC and should be exploited for future treatments.

Original publication

DOI

10.18632/oncotarget.12022

Type

Journal article

Journal

Oncotarget

Publication Date

08/11/2016

Volume

7

Pages

72819 - 72832

Keywords

desmoplastic stroma, hypoxia, macrophages, prognosis, vessel density, Aged, Aged, 80 and over, Antigens, CD, Antigens, CD20, Antigens, Differentiation, Myelomonocytic, Antigens, Neoplasm, Biomarkers, Tumor, Carbonic Anhydrase IX, Carcinoma, Pancreatic Ductal, Combined Modality Therapy, Female, Humans, Hypoxia, Immunohistochemistry, Macrophages, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Neovascularization, Pathologic, Pancreatic Neoplasms, Platelet Endothelial Cell Adhesion Molecule-1, Prognosis, Stromal Cells, Survival Analysis